276-286.
Department of Anesthesiology, Hatyai Hospital, Songkhla, Thailand.
*Corresponding author: Amporn Thongphut E-mail: ampornthongphut@gmail.com
Received 16 January 2026 Revised 2 March 2026 Accepted 2 March 2026 ORCID ID: http://orcid.org/0009-0006-2422-7965 https://doi.org/10.33192/smj.v78i4.279908
All material is licensed under terms of the Creative Commons Attribution 4.0 International (CC-BY-NC-ND 4.0) license unless otherwise stated.
ABSTRACT
INTRODUCTION
Spinal anesthesia is widely used in elderly patients undergoing hip fracture surgery because of its favorable safety profile and lower risk of postoperative complications compared with general anesthesia.1,2 However, hypotension following spinal anesthesia remains a common and clinically significant complication,3–5 particularly in elderly individuals, who often have reduced physiological reserves, multiple comorbidities, and polypharmacy.6
Hypotension after spinal anesthesia is mainly caused by sympathetic blockade, which produces arterial and venous vasodilation, reduced systemic vascular resistance, and decreased venous return. Maintenance of arterial pressure under these conditions relies on compensatory vasoconstrictive mechanisms, including activation of the renin–angiotensin–aldosterone system (RAAS). Consequently, patients receiving RAAS inhibitors, such as angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, may be more susceptible to hypotension, as these agents blunt angiotensin II–mediated vasoconstriction and limit hemodynamic compensation during sympathetic blockade.
Several factors have been associated with post-spinal hypotension in older adults, including advanced age, higher American Society of Anesthesiologists physical status, baseline blood pressure, preoperative antihypertensive
therapy, and intrathecal local anesthetic dose.5,7-8 Among these factors, preoperative antihypertensive medication use is potentially modifiable. Although these medications are commonly prescribed for elderly patients with hypertension or cardiovascular comorbidities, their independent effect on hypotension following spinal anesthesia remains unclear. Previous studies have reported inconsistent results, and evidence specifically addressing patients aged ≥80 years—who are particularly vulnerable to hypotension-related complications—remains limited.9–11 Therefore, this study aimed to evaluate the association
between preoperative antihypertensive use and the occurrence of hypotension after spinal anesthesia in patients aged ≥ 80 years undergoing hip fracture surgery, based on secondary analysis of retrospective cohort data.
MATERIALS AND METHODS
This study was a retrospective secondary analysis of data derived from a previous investigation of post-spinal hypotension in elderly patients. Patients aged 80 years or older who underwent hip fracture surgery under spinal anesthesia at a tertiary referral center in Southern Thailand between October 1, 2016, and September 30, 2023, were included. The study protocol was approved by the Institutional Ethics Committee.
All patients aged ≥80 years who underwent hip fracture surgery under spinal anesthesia during the study period were screened. Patients were excluded if they had incomplete medical records, failed or inadequate spinal anesthesia, required deep sedation, had pre-existing hypotension, or received vasoactive agents prior to induction of anesthesia.
Patients were categorized according to whether antihypertensive medications were taken on the day of surgery prior to spinal anesthesia. Antihypertensive agents were classified into the following groups: renin–angiotensin–aldosterone system (RAAS) antagonists, beta-blockers, calcium channel blockers, diuretics, and alpha-blockers. The total number of antihypertensive agents used by each patient was also recorded. Preoperative antihypertensive exposure was defined as medications actually administered on the morning of surgery by ward nurses, based on medication administration records documented in the medical charts.
The primary outcome was post-spinal hypotension, defined as systolic blood pressure <90 mmHg or a >20% reduction from baseline within one hour after spinal anesthesia. Blood pressure was measured at 1-minute intervals during the first 10 minutes and every 5 minutes thereafter according to institutional monitoring protocols. A single measurement meeting either criterion was considered hypotension. Patients receiving prophylactic vasopressors were excluded to avoid masking hypotension incidence.
Data were extracted from electronic medical records and included demographic characteristics (age, sex, and body mass index), comorbidities, American Society of Anesthesiologists (ASA) physical status classification, fracture type, surgical procedure, baseline blood pressure measured in the ward prior to transfer to the operating room, and preoperative laboratory values. Intraoperative variables included anesthetic technique, intrathecal drug administration, hemodynamic parameters, fluid administration, vasopressor use, and operative duration. Spinal anesthesia was performed according to institutional routine practice. After standard monitoring was established, intravenous crystalloid or colloid loading (preload or co-load) was administered at the attending anesthesiologist’s discretion. Patients were placed in the lateral decubitus position, and spinal anesthesia was
performed using standard aseptic technique.
A midline or paramedian approach at the L2–3, L3–4, or L4–5 interspace was used with a 25–27G spinal needle. Hyperbaric or isobaric bupivacaine was administered intrathecally, with the dose determined by the attending anesthesiologist. Intrathecal opioids (fentanyl or morphine) were added at discretion.
After injection, patients were generally maintained in the lateral position for approximately 5 minutes. Sensory block level was assessed using cold or pinprick testing until approximately 10 minutes post-block according to institutional protocol. The highest sensory level, when available, was included in the analysis. No fixed institutional protocol for fluid loading or prophylactic vasopressor administration was used during the study period.
As this study was a secondary analysis of existing retrospective data, no prospective sample size calculation was performed. All eligible patients from the original dataset who met the inclusion criteria were included. A post hoc power estimation based on the adjusted risk ratio for RAAS antagonist use (RR 1.38; 95% CI 1.13–1.68) and its corresponding standard error indicated an approximate statistical power of 89% at a two-sided alpha level of 0.05 for detecting this association.
The distribution of continuous variables was assessed for normality using graphical methods and the Shapiro–Wilk test. Normally distributed variables were presented as mean ± standard deviation and compared using Student’s t-test, whereas non-normally distributed variables were summarized as median (interquartile range) and compared using the Mann–Whitney U test. Categorical variables were expressed as frequencies and percentages and compared using Fisher’s exact test because of small expected cell counts.
Univariable and multivariable risk ratio regression analyses were performed using a generalized linear model with a Poisson distribution and robust variance estimation to identify factors associated with post-spinal hypotension. Variables deemed clinically relevant or with a p-value <0.05 in univariable analysis were entered into the multivariable model. Results were reported as risk ratios (RRs) with 95% confidence intervals (CIs). Missing data were handled using complete-case analysis. All statistical tests were two-sided, and a p-value <0.05 was considered statistically significant. Statistical analyses were conducted using Stata version 16.0 (StataCorp, College Station, TX, USA).
RESULTS
A total of 319 patients aged ≥80 years who underwent hip fracture surgery under spinal anesthesia were included. Of these, 233 patients (73.0%) received preoperative antihypertensive medication. Baseline characteristics of the study population are summarized in Table 1. Patients in the antihypertensive group were more frequently female and had higher American Society of Anesthesiologists (ASA) physical status classifications. Comorbidities were more prevalent in this group, including hypertension, prior cerebrovascular accident, and chronic kidney disease stage 3–5. No significant differences were observed in age, body mass index, baseline blood pressure, or most preoperative laboratory parameters between groups.
Intraoperative characteristics are shown in Table 2. The distribution of fracture types and surgical procedures differed significantly between groups. Intertrochanteric fractures were more common in patients not receiving antihypertensive medication, whereas arthroplasty procedures were more frequent in those receiving antihypertensive therapy. The mean dose of hyperbaric bupivacaine was lower in the antihypertensive group, and intrathecal morphine was used more frequently. There were no significant differences between groups in operative time, estimated blood loss, anesthetic level, vasopressor use, or type and volume of fluid preload.
Exclusion:
General anesthesia (n=119)
Pre-existing hypotension (n=0)
Vasoactive agent used before spinal anesthesia (n=5)
-Failed or inadequate spinal block (n=8)
Required deep sedation (n=12)
Incomplete anesthetic records (n=0)
Included for analysis (n=319)
Patients aged ≥ 80 years with primary diagnosis ICD 10: S720, S721, S722 and procedure code ICD 9 CM: 79.15, 79.25,79.35, 81.51, 81.52 identified from hospital database (n=463)
Spinal anesthesia characteristics according to RAAS
antagonist exposure are summarized in Table 3. No significant between-group difference in sensory block level was observed. Similarly, intrathecal local anesthetic type and dose, as well as intrathecal opioid use, were comparable between groups.
The overall incidence of post-spinal hypotension was 63.0%. The incidence was 64.8% in patients who received preoperative antihypertensive medication and 58.1% in those who did not, with no statistically significant difference between groups (Table 4). When stratified by antihypertensive drug class, higher incidences of hypotension were observed among patients receiving renin–angiotensin–aldosterone system (RAAS) antagonists and beta-blockers. A significant dose–response trend was observed between the number of concurrent antihypertensive agents and the incidence of hypotension, with the highest incidence observed among patients receiving four agents (Fig 2).
Multivariable risk ratio regression analysis adjusted for age, sex, body mass index, ASA classification, comorbidities, fracture type, baseline blood pressure, hemoglobin level, intrathecal local anesthetic type and dose, intrathecal opioid, fluid administration, anesthetic level, and time to surgery demonstrated that overall preoperative antihypertensive use was not independently associated with post-spinal hypotension (adjusted RR
= 1.00; 95% CI, 0.72–1.40; p = 0.981). The use of RAAS
With antihypertensive premedication (n=233)
Without antihypertensive premedication (n=86)
Fig 1. Study flow diagram
TABLE 1. Patients’ characteristics.
Characteristics | With antihypertensive medication | Without antihypertensive medication | p value |
n=233 (73%) | n=86 (27%) | ||
Female | 201 (86.3) | 62 (72.1) | 0.005* |
Age (years) | 85.2 ± 4.0 | 85.8 ± 4.2 | 0.288 |
Height (cm) | 153.8 ± 7.8 | 152.8 ± 6.1 | 0.314 |
Body mass index (kg/m2) | 21.9 ± 4.1 | 21.1 ± 4.0 | 0.099 |
ASA classification | <0.001* | ||
II | 25 (10.7) | 27 (31.4) | |
III-IV | 208 (89.3) | 59 (68.6) | |
Comorbidity | 232 (99.6) | 49 (57.0) | <0.001* |
Hypertension | 229 (98.3) | 25 (29.1) | <0.001* |
Previous/History of myocardial infarction | 8 (3.4) | 1 (1.2) | 0.453 |
Previous/History of cerebrovascular disease | 35 (15.0) | 4 (4.7) | 0.012* |
Chronic kidney disease stage 3-5 | 36 (15.5) | 2 (2.3) | 0.001* |
COPD | 17 (7.3) | 11 (12.8) | 0.179 |
Dementia | 11 (4.7) | 3 (3.5) | 0.766 |
Laboratory value | |||
Admission hemoglobin (gm/dl) | 10.8 ± 1.9 | 10.6 ± 1.9 | 0.305 |
Preoperative hematocrit (%) | 34 ± 3.4 | 33.7 ± 3.3 | 0.537 |
Blood urea nitrogen (mg/dl) | 16 (13, 22) | 16 (12, 23) | 0.892 |
Creatinine (mg/dl) | 0.79 (0.64, 1.08) | 0.75 (0.62, 1.03) | 0.359 |
eGFR (ml/min/1.73 m2) | 71.0 ± 26.1 | 76.0 ± 26.0 | 0.125 |
Albumin (g/dl) | 3.6 ± 0.5 | 3.5 ± 0.4 | 0.678 |
Baseline SBP (mmHg) | 135.6 ± 17.0 | 134.1 ± 17.7 | 0.480 |
Baseline DBP (mmHg) | 71.6 ± 10.8 | 72.5 ± 11.2 | 0.510 |
Preoperative transfusion (unit) | 0 (0, 1) | 0 (0, 1) | 0.931 |
Values are presented as mean ± SD, number (%), and median (Q1, Q3)
antagonists remained significantly associated with post-spinal hypotension (adjusted RR = 1.38; 95% CI, 1.13–1.68; p = 0.002). When the combined effect of multiple antihypertensive agents was evaluated, a significant dose–response trend was observed between the number
of concurrent medications and the risk of hypotension. Patients receiving three or more antihypertensive agents exhibited the highest adjusted risk, although this was not statistically significant (adjusted RR = 1.45; 95% CI, 0.96–2.17; p = 0.074) (Table 5 and Fig 3).
TABLE 2. Intraoperative prognostic factors.
Prognostic factor | With antihypertensive n=233 (73%) | Without antihypertensive n=86 (27%) | p value |
Injury to surgery (days) | 5 (3, 8) | 4 (2, 7) | 0.014* |
Type of fracture Neck | 94 (40.3) | 21 (24.4) | 0.015* |
Intertrochanteric | 136 (58.4) | 62 (72.1) | |
Subtrochanteric | 3 (1.3) | 3 (3.5) | |
Operation Arthroplasty | 86 (36.9) | 21 (24.4) | 0.045* |
Fixation | 147 (63.1) | 65 (75.6) | |
Intrathecal bupivacaine Hyperbaric | 26 (11.2) | 8 (9.3) | 0.838 |
Isobaric | 207 (88.8) | 78 (90.7) | |
0.5% Hyperbaric bupivacaine dose (ml) | 2.5 ± 0.4 | 2.9 ± 0.4 | 0.022* |
0.5% Isobaric bupivacaine dose (ml) | 2.7 ± 0.3 | 2.6 ± 0.4 | 0.458 |
Intrathecal opioid Morphine | 30 (12.9) | 5 (5.8) | 0.043* |
Fentanyl | 3 (1.3) | 4 (4.7) | |
Anesthetic level ≥ T6 | 41 (17.6) | 12 (14.0) | 0.556 |
Below T6 | 144 (61.8) | 52 (60.4) | |
Undetermined | 48 (20.6) | 22 (25.6) | |
Operative time (min) | 59.2 ± 26.7 | 61.4 ± 24.3 | 0.498 |
Estimated blood loss (ml) | 100 (50, 200) | 100 (50, 250) | 0.838 |
Intravenous sedation | 171 (73.4) | 54 (62.8) | 0.073 |
Fluid preload/ co-load Crystalloid | 132 (56.7) | 46 (53.5) | 0.614 |
Colloid | 101 (43.4) | 40 (46.5) | |
Crystalloid volume (ml) | 454.9 ± 179.9 | 437.0 ± 191.6 | 0.567 |
Colloid volume (ml) | 353.5 ± 124.3 | 395.0 ± 102.4 | 0.063 |
Values are presented as mean ± SD, number (%), and median (Q1, Q3)
TABLE 3. Spinal anesthesia characteristics by RAAS antagonist exposure.
Anesthetic characteristics | RAAS antagonist n=70 (21.9%) | Non-RAAS antagonist n=249 (78.1%) | p-value |
Intrathecal bupivacaine Hyperbaric Isobaric | 7 (10.0) 63 (90.0) | 27 (10.8) 222 (89.2) | 1.000 |
0.5% Hyperbaric bupivacaine dose (ml) | 2.5 ± 0.3 | 2.6 ± 0.4 | 0.509 |
0.5% Isobaric bupivacaine dose (ml) | 2.7 ± 0.3 | 2.7 ± 0.4 | 0.091 |
Intrathecal opioid Morphine Fentanyl | 11 (15.7) 0 (0.0) | 24 (9.6) 7 (2.8) | 0.156 |
Anesthetic level† ≥ T6 | 13 (21.0) | 40 (21.4) | 1.000 |
Below T6 | 49 (79.0) | 147 (78.6) |
Values are presented as mean ± SD, and number (%)
†Analysis of anesthetic level was performed after excluding cases with an undocumented sensory level.
TABLE 4. Antihypertensive premedication and risk of post-spinal hypotension.
Type and combination of | Total (n=319) | Risk of hypotension | p value |
antihypertensive premedication | |||
Premedication | 0.297 | ||
No | 86 (27.0) | 50 (58.1) | |
Yes | 233 (73.0) | 151 (64.8) | |
Type | |||
Calcium blocker | 210 (65.8) | 135 (64.3) | 0.542 |
RAAS antagonist | 70 (21.9) | 52 (74.3) | 0.035* |
Beta blocker | 35 (11.0) | 28 (80.0) | 0.027* |
Diuretic | 25 (7.8) | 20 (80.0) | 0.084 |
Alpha blocker | 7 (2.2) | 5 (71.4) | 1.000 |
Combination | 0.004** | ||
0 | 86 (27.0) | 50 (58.1) | |
1 | 143 (44.8) | 84 (58.7) | |
2 | 72 (22.6) | 50 (69.4) | |
3 | 13 (4.1) | 12 (92.3) | |
4 | 5 (1.6) | 5 (100) |
Values are presented as number (%), **p value for trend
Fig 2. Incidence of post-spinal hypotension according to the number of antihypertensive agents. The incidence increased progressively with the number of agents, suggesting a dose–response relationship (P for trend = 0.004).
TABLE 5. Risk of post-spinal hypotension.
Antihypertensive | Univariable RR | Multivariable RR† | 95% CI | p value |
Premedication | ||||
No | ref | ref | ref | |
Yes | 1.11 | 1.00 | 0.72 – 1.40 | 0.981 |
Type | ||||
Calcium channel blocker | 1.06 | 0.98 | 0.76 – 1.27 | 0.891 |
RAAS antagonist | 1.24 | 1.38 | 1.13 – 1.68 | 0.002* |
Beta blocker | 1.31 | 1.10 | 0.84 – 1.45 | 0.476 |
Diuretic | 1.30 | 1.07 | 0.80 – 1.43 | 0.656 |
Alpha blocker | 1.14 | 1.05 | 0.53 – 2.06 | 0.898 |
Combination | 0.036** | |||
0 | ref | ref | ref | |
1 | 1.01 | 0.93 | 0.66 – 1.31 | 0.679 |
2 | 1.19 | 1.06 | 0.74 – 1.52 | 0.755 |
≥ 3 | 1.62 | 1.45 | 0.96 – 2.17 | 0.074 |
†adjusted for age, sex, height, BMI, co-morbidities, ASA, hemoglobin level, baseline blood pressure, time to surgery after injury, fracture type and surgery, local anesthetic type and dose, intrathecal opioid, intravenous fluid pre-load type and volume, and anesthetic level.
**p value for trend, RAAS antagonist: renin–angiotensin–aldosterone system antagonist.
Fig 3. Adjusted risk ratios for post-spinal hypotension according to the number of antihypertensive agents. Squares represent adjusted risk ratios and horizontal lines indicate 95% confidence intervals. The dashed vertical line indicates a risk ratio of 1. A dose–response trend was observed (P for trend = 0.036).
DISCUSSION
This secondary analysis demonstrated that overall preoperative antihypertensive medication use was not independently associated with post-spinal hypotension in patients aged 80 years and older undergoing hip fracture surgery. However, the use of renin–angiotensin–aldosterone system (RAAS) antagonists was associated with an increased risk of hypotension. In addition, a dose–response relationship was observed between the number of concurrent antihypertensive agents and the incidence of post-spinal hypotension.
These findings suggest that not all antihypertensive medications pose the same hemodynamic risk in the setting of spinal anesthesia. RAAS antagonists may impair compensatory vasoconstrictive responses following sympathetic blockade, thereby predisposing elderly patients to hypotension. Similar sensory block levels and comparable intrathecal opioid use between RAAS antagonist and non-RAAS antagonist groups suggest that differences in anesthetic technique were unlikely to explain the findings. These findings are consistent with a previous report identifying RAAS antagonists, including ACE inhibitors and angiotensin receptor blockers, as contributors to perioperative hypotension.12 However, another study found that long-term ACEI therapy, even when continued until the morning of surgery, did not significantly influence early post-spinal blood pressure changes.13
These observations should be interpreted in the
context of contemporary perioperative cardiovascular recommendations. The 2024 AHA/ACC/ACS guideline suggests that temporary omission of RAAS inhibitors before elevated-risk noncardiac surgery may reduce intraoperative hypotension in selected patients treated for hypertension (Class IIb recommendation).14 The present findings are broadly aligned with this perspective. However, the same guideline supports continuation of RAAS inhibitors in patients with heart failure with reduced ejection fraction (Class IIa), emphasizing individualized perioperative management based on underlying indication. In this frail elderly cohort, temporary withholding may be considered when hypertension is the primary indication. In this study, no significant association was observed between beta-blocker or calcium channel blocker use and post-spinal hypotension, although the relatively small subgroup sizes may have limited statistical power. Previous studies have reported conflicting results. Kaimar et al. and Parasuram et al. found no increased incidence of hypotension among patients receiving calcium channel blockers or beta-blockers, although the former required greater vasopressor use.11,15 In contrast, Dohare et al. and Prasad et al. reported higher rates of post-spinal hypotension in hypertensive patients on calcium channel blockers compared with those on beta-blockers or normotensive
controls.10,16
Although diuretics are widely used for the management of hypertension and heart failure, alpha-blockers are commonly prescribed for hypertension or benign prostatic
hypertrophy in elderly patients. In this study, no significant association between their use and post-spinal hypotension was found. Evidence directly addressing the relationship between these drug classes and spinal anesthesia–induced hypotension remains limited. Diuretics may predispose patients to hypovolemia or electrolyte disturbances, while alpha-blockers reduce systemic vascular resistance through alpha-1 antagonism, thereby increasing the risk of perioperative hypotension, particularly with nonselective or alpha-1 selective agents.17 However, the current evidence is insufficient to establish a definitive causal link, underscoring the need for well-designed prospective studies to further clarify the hemodynamic effects of these agents in patients undergoing neuraxial anesthesia.
Resistant hypertension, defined as uncontrolled blood pressure despite the use of three or more antihypertensive agents or controlled blood pressure requiring four or more drugs, is more prevalent among older adults and those with diabetes or chronic kidney disease.18 In this study, a significant dose–response relationship was observed between the number of concurrent antihypertensive agents and the incidence of post-spinal hypotension (p for trend
= 0.036). Although patients receiving three or more agents demonstrated the highest adjusted risk, the association was not statistically significant. The concurrent use of multiple antihypertensive drugs may induce complex alterations in sympathetic tone, vascular compliance, and baroreceptor responsiveness,19 thereby modifying the normal cardiovascular adaptation to spinal anesthesia. Clinicians should therefore consider both the number and pharmacologic mechanisms of antihypertensive agents when evaluating perioperative hemodynamic risk in elderly patients.
This study has limitations. First, as a retrospective analysis, causal relationships cannot be established, and unmeasured confounding may exist. Second, although antihypertensive use was defined based on medications administered on the morning of surgery according to medication administration records, the exact timing relative to spinal anesthesia was not available in the original dataset. Third, the definition of hypotension relied on intraoperative records, which may vary in accuracy. Finally, the study focused on the occurrence of hypotension without evaluating its duration, severity, or related clinical outcomes, which may have underestimated its clinical impact. Future prospective studies incorporating precise medication timing, standardized definitions of hypotension, and clinically relevant outcomes are needed to better define the impact of preoperative antihypertensive therapy on perioperative hemodynamics in elderly patients.
Randomized or carefully controlled observational studies focusing on RAAS antagonists and combination therapy may better guide perioperative medication management in very elderly patients undergoing spinal anesthesia.
CONCLUSIONS
Preoperative antihypertensive use was not independently associated with post-spinal hypotension in patients aged
≥80 years undergoing hip fracture surgery. However, risk differed by drug class, with RAAS antagonists independently associated with increased hypotension. These findings suggest that hemodynamic vulnerability may relate more to medication class than overall antihypertensive use. Individualized preoperative management, particularly in patients receiving RAAS antagonists or combination therapy, may improve perioperative hemodynamic stability.
The datasets generated and/or analyzed during the current study are not publicly available due to institutional restrictions and the presence of sensitive patient information but are available from the corresponding author on reasonable request and with permission from the Institutional Ethics Committee.
ACKNOWLEDGEMENTS
The author gratefully acknowledges Prof. Jayanton Patumanond, Dr. Noraworn Jirattikanwong, and Dr. Nop Khongthon for their valuable statistical consultation.
DECLARATIONS
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
The author declares no conflict of interest.
TCTR20260108005
The author contributed to conceptualization, methodology, investigation, formal analysis, visualization, and manuscript preparation, including writing the original draft as well as review and editing. The author has read and approved the final version of the manuscript.
The author used ChatGPT (OpenAI, San Francisco,
CA, USA) for assistance with language editing and grammatical revision of the manuscript. All content was reviewed and approved by the author.
REFERENCES
Helwani MA, Avidan MS, Ben Abdallah A, Kaiser DJ, Clohisy JC, Hall BL, et al. Effects of regional versus general anesthesia on outcomes after total hip arthroplasty: a retrospective propensity-matched cohort study. J Bone Joint Surg Am. 2015;97(3):186–93.
Han F, Yang Y, Tian X. Impact of regional anesthesia vs general anesthesia on postoperative outcomes in elderly patients with hip fracture: a meta-analysis. Investig Clin. 2025;66(2):217–30.
Hartmann B, Junger A, Klasen J, Benson M, Jost A, Banzhaf A, et al. The incidence and risk factors for hypotension after spinal anesthesia induction: an analysis with automated data collection. Anesth Analg. 2002;94(6):1521–9.
Chinachoti T, Saetia S, Chaisiri P, Tritrakarn T. Incidence and risk factors of hypotension and bradycardia during spinal anesthesia. Siriraj Med J. 2006;58(3):696-701.
Malima ZA, Torborg A, Cronjé L, Biccard BM. Predictors of post-spinal hypotension in elderly patients: a prospective observational study in the Durban Metropole. South Afr J Anaesth Analg. 2019;25(5):13–7.
Dominguez JE, Halaszynski TM. Perioperative regional anesthesia in the elderly. In: Hadzic A, editor. Hadzic’s textbook of regional anesthesia and acute pain management. 2nd ed. New York: McGraw-Hill Education; 2017.p.865-80.
Akarapatima R, Wongwiwattananon W, Pakpirom J, Benjhawaleemas P. The risk factors for spinal anesthesia–induced hypotension in patients undergoing hip fracture surgery among the elderly: a retrospective cohort study. Thai J Anesthesiol. 2021;47(2):85–92.
Jitsinthunun T, Supannanont P, Raksakietisak M. Incidence, Risk-factors, and Outcomes of Intraoperative Hypotension Following Spinal Anesthesia in Hip Fracture Surgery: A Retrospective Study from Thailand. Siriraj Med J. 2024;76(7): 395-405.
S AK, Oommen TG, Thomas CW, Jose DE, VS AV, R GS, et al. An observational study to compare spinal anesthesia-induced hemodynamic changes in normotensive and hypertensive patients on antihypertensive medications. Eur J Cardiovasc
Med. 2024;14:1096–102.
Dohare S, Vatsalya T, Mehrotra S. An observational study to compare spinal anesthesia-induced hemodynamic changes in normotensive and hypertensive patients on antihypertensive medications. Asian J Pharm Clin Res. 2024;17(2):26–30.
Kaimar P, Sanji N, Upadya M, Mohammed KR. A comparison of hypotension and bradycardia following spinal anesthesia in patients on calcium channel blockers and β-blockers. Indian J Pharmacol. 2012;44(2):193–6.
Calloway JJ, Memtsoudis SG, Krauser DG, Ma Y, Russell LA, Goodman SM. Hemodynamic effects of angiotensin inhibitors in elderly hypertensives undergoing total knee arthroplasty under regional anesthesia. J Am Soc Hypertens. 2014;8(9):644–51.
Höhne C, Meier L, Boemke W, Kaczmarczyk G. ACE inhibition does not exaggerate the blood pressure decrease in the early phase of spinal anaesthesia. Acta Anaesthesiol Scand. 2003; 47(7):891–6.
Thompson A, Fleischmann KE, Smilowitz NR, de las Fuentes L, Mukherjee D, Aggarwal NR, et al. 2024 AHA/ACC/ACS/ ASNC/HRS/SCA/SCCT/SCMR/SVM guideline for perioperative cardiovascular management for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;150(19):e351–442.
Parasuram T, Nadagoudar H. Comparison of effect of spinal anesthesia on heart rate and blood pressure between hypertensive patients on β-blockers or calcium channel blockers and normotensive patients: a prospective observational cohort study. Int J Med Anesthesiol. 2021;4(2):7–11.
Prasad AP, Prakash G, Dubey S, Kamendu A, Kumar H. To compare the haemodynamic parameters in patients on calcium channel blockers and beta blockers undergoing subarachnoid block. Int J Pharm Sci Rev Res. 2022;75(2):174–9.
OpenAnesthesia. Alpha blockers [Internet]. [cited 2025 Sep 14]. Available from: https://www.openanesthesia.org/keywords/ alpha-blockers/
Flack JM, Buhnerkempe MG, Moore KT. Resistant hypertension: disease burden and emerging treatment options. Curr Hypertens Rep. 2024;26(5):183–99.
Colle SD, Morello F, Rabbia F, Milan A, Naso D, Puglisi E, et al. Antihypertensive drugs and the sympathetic nervous system. J Cardiovasc Pharmacol. 2007;50(5):487–93.